Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024
ARMAN YURISALDI SALEH, Dwi Arwandi Yogi Saputra, Riezky Valentina, Tirta Darmawan Susanto, Tasawar Iqbal, ARMAN YURISALDI SALEH
TL;DR
This study uses bibliometric analysis to explore research trends on Ginkgo Biloba as a cognitive enhancer, using data from the Scopus database.
Contribution
The novelty lies in focusing on Ginkgo Biloba as a niche cognitive enhancer through bibliometric analysis of Scopus literature.
Findings
Ginkgo Biloba is a widely studied cognitive enhancer with historical and therapeutic significance.
Bibliometric analysis reveals key trends, influential authors, and research gaps in cognitive enhancer studies.
The study provides guidance for future research on cognitive enhancers based on literature trends.
Abstract
Cognitive enhancers, also known as nootropics, aim to improve cognitive functions, such as memory and attention. Despite their potential benefits, the challenges include scientific validation, ethical considerations, and regulatory hurdles. This bibliometric study analyzes literature from Scopus to identify key trends, influential authors, and research gaps, providing guidance for future research. This study employs a literature review methodology to gather data from the Scopus database on Neuroaid, analyzing it using Biblioshiny and VOSviewer software. The focus was on Ginkgo Biloba as a niche-theme cognitive enhancer agent based on Scopus data, using both quantitative and qualitative analyses. Ginkgo biloba, the 'maidenhair tree’ from the order Ginkgoales, appeared 290 million years ago. Chinese and Japanese culture has been cultivated for thousands of years. This tree is valued for…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGinkgo biloba and Cashew Applications · Coenzyme Q10 studies and effects · Attention Deficit Hyperactivity Disorder
Introduction
Cognitive enhancers, also known as nootropics or smart drugs, have garnered significant attention from both the scientific community and popular culture. These substances are designed to improve cognitive functions, such as memory, attention, and problem-solving abilities in both healthy individuals and those experiencing cognitive decline. ^ 1 ^ The growing interest in cognitive enhancers is driven by their potential benefits in enhancing mental performance, which can be particularly valuable in competitive environments such as academia and the workplace. ^ 2 ^
Despite the promising potential of cognitive enhancers, this field faces several challenges, including the need for rigorous scientific validation, ethical considerations, and regulatory hurdles. ^ 3 ^ The current body of literature on cognitive enhancers is vast and diverse, encompassing studies on various pharmacological agents, non-pharmacological interventions, and their effects on different cognitive domains. ^ 4 ^ However, there is a lack of a comprehensive bibliometric analysis that systematically reviews and synthesizes this body of research.
This bibliometric study aimed to fill this gap by providing a comprehensive analysis of the existing literature on cognitive enhancers indexed in Scopus. By employing bibliometric methods, this study identified key trends, influential authors, and research gaps in the field. The findings of this study will contribute to a better understanding of the current state of research on cognitive enhancers and inform future research.
The methodology of this study involved the collection and analysis of data from Scopus, focusing on articles published between 1988 and 2024. The data will be analyzed using various bibliometric techniques, including co-citation, keyword, and network analyses. The results are presented in the form of visualizations and descriptive statistics, providing a clear and comprehensive overview of the research landscape.
The significance of this study lies in its potential to inform policy decisions, guide research funding and shape the development of cognitive enhancers. By identifying the most impactful studies and emerging trends, this bibliometric analysis will help researchers and policymakers prioritize areas of research that are likely to yield the greatest benefits.
Methods
Bibliometric research is a methodological approach that employs scientific publishing data to delineate and examine the evolution of scientific disciplines. This study seeks to find and delineate trends, patterns, and correlations within scientific texts pertaining to specific subjects. This research focuses on the subject of "cognitive enhancers." This study used data from www.scopus.com, a prominent and reputable database for scientific articles. This study was conducted in December, 2024.
To carry out bibliometric research, the steps to follow are as follows:
-
1.Determining the search keywords. In this study, the keywords used were focused on cognitive enhancers. These keywords were entered into the search column at www.scopus.com by selecting the topic field (title, abstract, keywords).
-
2.Filter search results. In this study, Were not filtered.
-
3.Retrieved data from search results. This study involved the retrieval of search result data in three distinct formats.
-
•CSV (comma-separated value) contains basic information about the document, such as title, author, affiliation, year, source, abstract, and keywords.
-
•RIS (research information system), which contains detailed information about a document, including the references cited by the document.
Data Collection
A search was conducted on the Scopus website using the specified terms, with the understanding that this platform encompasses research deemed to possess validity: TITLE – ABS – KEY (“cognitive enhancer”) are the titles of the products under consideration. We received twenty documents were received by us. We then saved the document from Scopus in the form of a file with extension.csv following this step.
Data Analysis
Both the Biblioshiny and Vosviewer software packages were utilised in the analysis process.
Quantitative Analysis
Documents by Year
Figure 1 indicates an increase in the number of documents, culminating in 61 papers by 2023. The earliest document dates back to 1988 and comprises two papers titled "Antagonism by Exifone, a New Cognitive Enhancing Agent, of the Amnesias Induced by Four Benzodiazepines in Mice," authored by Porsolt, R.D., Lenègre, A., Avril, I., and Doumont, G. The second document, headed "Comparison of the Effects of Vinpocetine, Vincamine, and Nicergoline on the Normal and Hypoxia-Damaged Learning Process in Spontaneously Hypertensive Rats," is authored by Groó, D., Pálosi, É., and Szporny, L. As of 2024, there are 54 documents, with the most recent titled "MSK 1," which is essential for the experience- and ampakine-dependent strengthening of spatial reference memory and reversal learning, as well as for the induction of Arc and BDNF written by Morè et al. ^ 7 ^
Documents by year.
Most Relevant Sources.
Most Relevant Sources
According to Figure 3. Neuropharmacology occupies the foremost position. This contains information regarding the journal neuropharmacology. The journal has been indexed in Scopus since 1962. The current SCImago Journal Rank (SJR) for this journal was 1.307. It was published by Elsevier Ltd. The journal publishes high-quality original research in neuroscience, concentrating on the examination and comprehension of the effects of exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. This journal is classified as Q1 in the fields of cellular and molecular neuroscience, and pharmacology. Psychopharmacology has been indexed in Scopus since 1959. The most recent SJR is 1.053. SCImago quartile classification, Q1 (highest). This magazine accepts many manuscripts, including experimental studies on the impact of medications on human cognition and behavior as well as laboratory investigations involving experimental animals. It also invites works that incorporate various levels of analysis, ranging from neurochemical assays to functional neuroimaging research. Ranking three is the Journal of Behavioral Brain Research. This contains information regarding the Journal of Behavioral Brain Research. This journal has been indexed in Scopus since the 1980. The most recent data indicate that the SCImago Journal Rank (SJR) for Behavioral Brain Research is 0.881. This study was published by Elsevier B.V. This magazine welcomes diverse forms of submission, encompassing original research, methodological innovations, and critical analyses within the domains of neuroscience, behavioral science, and cognitive science. This journal is classified as Q2.
Most Global Cited Documents.
Most Global Cited Documents
According to Figure 3, the most cited document, with 1059 citations, is the journal titled Identification of separable cognitive factors in schizophrenia, authored by Keith H. Nuechterlein, Deanna M. Barch, James M. Gold, Terry E. Goldberg, Michael F. Green, and Robert K. Heaton. The journal's abstract states that one of the main objectives of this research was to identify separate cognitive factors in schizophrenia. This study aimed to better understand how this disorder affects various cognitive aspects, such as memory ability, attention, and information processing.
Second, with 946 citations, a document titled "Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinction of Fear" was authored by Kerry J. Ressler, MD, PhD; Barbara O. Rothbaum, PhD; Libby Tannenbaum, PhD; and colleagues. Background: This study evaluated the use of D-cycloserine (DCS), a partial agonist of N-methyl-D-aspartate (NMDA) receptors, as an adjunct to exposure therapy for individuals with phobias. Previous studies have demonstrated that DCS can accelerate fear extinction in animals.
The third-ranked document, with 623 citations, is titled Ionotropic and Metabotropic Glutamate Receptor Structure and Pharmacology. This review was published on February 25, 2005, in Psychopharmacology. The authors of this review were James N. C. Kew and John A. Kemp. This document discusses ionotropic and metabotropic glutamate receptors, which are two major receptors that function as primary excitatory neurotransmitters in the central nervous system (CNS).
Factorial Map Of The Documents With The Highest Contributes
In Figure 4, the most contributed manuscript, titled D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial" by JoAnn Difede, was published in Neuropsychopharmacology. The study was accepted on November 12, 2013, and published online on December 11, 2013.
Factorial map of the documents with the highest contributes.
This study discusses the use of D-cycloserine (DCS) to enhance the effectiveness of virtual reality exposure (VRE) therapy in patients with PTSD. The main goal was to determine whether DCS could improve psychotherapeutic effectiveness by accelerating the process of extinguishing fear and increasing neuroplasticity (the brain's ability to adapt and change).
Documents by Author
According to Figure 5. The three most prolific authors, each with 16 documents, are as follows: Sahakian, B.J., with many paper titles: Enhancement of the motor control network with methylphenidate in individuals with traumatic brain injury. Effects of atomoxetine on attentional bias towards drug-related signals in cocaine-dependent individuals Modafinil Enhances Episodic and Working Memory Cognition in Patients with Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Examining the Neuroscience and Societal Consequences of Cognitive Enhancers as well as the utilization of substances by healthy individuals to augment cognition, creativity, motivation, and enjoyment. ^ 8– 12 ^
Documents by Author.
The subsequent author with 14 publications is Steiner, H., whose articles include: Methylphenidate with or without fluoxetine triggers the restoration of cocaine-seeking behavior in rats. Vilazodone, an innovative SSRI antidepressant with 5-HT1A partial agonist characteristics, reduced the potentiation of chronic oral methylphenidate-induced dynorphin expression in the striatum of male adolescent rats. Fluoxetine amplifies the behavioral effects generated by methylphenidate: increased locomotion or stereotypies, and improved acquisition of cocaine self-administration. Concurrent Chronic Administration of Oral Methylphenidate and Fluoxetine During Adolescence: Behavioral Effects, and Fluoxetine Enhances Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum. ^ 13– 17 ^
The subsequent author with 14 publications is Wattanathorn, J., whose articles include: Effect of Single Administration of Mulberry Milk on the Cognitive Function of 6-12-Year-Old Children: Results from a Randomized, Placebo-Controlled, Crossover Study. Assessment of the neuroprotective and cognitive enhancement properties of Cucurbita moschata. Mung bean-derived protein protects against neurodegeneration and memory deficits in an animal model of menopause with obesity. The amalgamated extract of black sticky rice and dill enhances cognitive deficits following stroke in individuals with metabolic syndrome and functional beverages. A novel cognitive enhancer, comprising extracts of purple corn cob and pandan leaves, enhances spatial memory and hippocampal neuron density by improving extracellular signal-regulated protein kinase expression, cholinergic function, and oxidative status in ovariectomized rats. ^ 18– 22 ^
Documents by country or territory
Figure 6 indicates that the United States has the highest number of document creators, totaling 436 documents. The United Kingdom followed 206 documents, followed by Japan with 95. Germany possesses 90 documents, whereas Canada has 87.
Documents by country or territory.
Documents by Subject Area
Figure 7 shows a pie chart depicting the distribution of the documents by subject area. The graph shows the percentage of documents classified into different subject areas. The percentage details for each topic area were as follows: medicine: 25.2% or 614 documents. Neuroscience: 21.3% (518 documents) Pharmacology, Toxicology, and Pharmaceutics: 21.1% (513 documents) Biochemistry, Genetics, and Molecular Biology: 11.5% (280 documents) Psychology: 6.3% or 280 documents. Social Sciences: 2.7% or 65 documents. Chemistry: 2.6% or 64 documents. Nursing: 1.9% or 47 documents. Multidisciplinary: 1.8% or 44 documents. Agricultural and Biological Sciences: 1.7% or 41 documents, which is noteworthy as it illustrates the substantial dispersion of documents across several topic areas, with medicine comprising the largest percentage. It is crucial to comprehend the study or publication emphasis in various fields.
Documents by Subject Area.
Documents by affiliation
According to Figure 8, in first place, the producer of most documents is affiliated with the University of Cambridge with 33 documents, the second is affiliated with the University of Cambridge with 31 documents, and the Boston University with 21 documents.
Documents by affiliation.
Documents by funding sponsor
Referring to Figure 9, the sponsors that generate the highest number of documents for funding are the National Institutes of Health with 111 documents, followed by the National Institute of Mental Health with 68 documents, and the U.S. Department of Health and Human Services producing 67 documents.
Documents by funding sponsor.
Network Visualization.
Network Visualization
Figure 9 indicates that the examined areas remained unassociated with the other regions delineated by the edges. The domain encompasses agitation, anorexia, vomiting, caregiver, tremor, hypertension, dietary supplement, Ginkgo biloba extract, huperzine A, anti-inflammatory activity, oxidative stress, glutathione, malondialdehyde, plant extracts, chemical structure, drug synthesis, peptide fragment, amyloid beta-protein, ^ 1– 42 ^ in vitro studies, peptide fragments, protein, phosphorylation, calpain, animal, cell, nerve cell, phosphorylation, brain nerve cell, compounds, water maze, NMDA receptor 1, hippocampal CA1 region, BDNF, swimming, Morris water maze, reference memory, cues, choice behavior, mental recall, volunteer, normal human, crossover, procedure, double-blind method, randomized controlled trial, adolescent, impulsive behavior, phobia, substance-related disorders, clinical article, ethics, outcome assessment, universities, students, and students.
Overlay Visualization of Scopus, Database Using Vosviewer
According to Figure 11. In the overlay visualization, it appears that the keywords that are being researched a lot approaching 2016 are the parts colored yellow, namely gluthahione, malonaldehyde, metabolism, prescription, major clinical study, randomized controlled trial (t, addiction, student, students, universities, oxidative stress, chemistry, and nerve degeneration.
Overlay visualization of scopus, database using Vosviewer.
Density Visualization
This is illustrated in Figure 12. In the visual circulation density, it appears that the part that is already saturated with research is yellow, while the part that is not yet saturated is slightly yellow and dominantly green, namely keywords: agitation, vomiting, anorexia, ginkgo biloba extract, cholinesterase, oxidative stress, glutathione, malonaldehyde, galantamine, pain, dementia, tacrine, nerve degeneration, plant extracts, sertraline, tremor, hypertension, neuroprotection, choline, degenerative disease, trazodone, side effect, antipsychotics, pathogenesis, alzheimer disease, cholinesterase inhibitors, dietary supplements, piracetam, drug penetration, drug structure, randomized controlled trial (t, drug safety, amfebutamone, prazosin, protein phosphorylation, peptide fragments, prevalence, olanzapine, neuroleptic agent, anxiolytic agent, ritanserin, memory disorder, amyloid beta protein[1-42], psychotic disorders, prescription, reboxetine, clinical trial, guanfacine, drug synthesis, chemistry, molecular structure, drug structure, in vitro study, peptide fragments, treatment outcome, narcolepsy, cell count, spiro compounds, ethics, placebo, outcome assessment, central stimulant agent, drug abuse, stress, universities, major clinical study, middle aged, substance-related disorders, clinical article, adolescent, phobia, impulsive therapy, motivation, attention, adult, addiction, fear, reinforcement, recall, accuracy, normal human, volunteer, randomized controlled trial, double-blind method, crossover procedure, mental recall, choice behavior, brain function, dopamine, task performance, reaction time, conditioning, operant, frontal cortex, genotype, mental recall, choice behavior, facilitation, nmda receptor, bdnf, ca1 region, hippocampal, mice, inbred c57bl, injections, intraperitoneal, animal behavior, behavior, animal, analysis of variance, striatum, exploratory behavior, morris water maze, reference memory, swimming, water maze.
Density visualization.
Thematic Map
According to Figure 13, on the thematic map based on the title, the following is an explanation for each keyword in each quadrant in the thematic map resulting from the bibliometric analysis. Here is an explanation of the meaning of each quadrant in the thematic map, and examples of document titles relevant to keywords in each quadrant.
Thematic map.
Niche Themes (Upper-Left Quadrant):
Keywords: Biloba, ginkgo, formation. Niche themes are well-developed topics that are not central to the overall research field. This means that, although this research is important, it is not currently the main focus. Example Document Titles: Neuroprotective effects of Ginkgo biloba in Alzheimer's disease. Ginkgo biloba extract and cognitive function: A review of the literature. Formation of cognitive enhancers from natural sources: The case of Ginkgo biloba.
.Motor Themes (Upper-Right Quadrant): Keywords: receptor, brain, rat, effects, memory, rat. Meaning: Motor themes are well-developed and central to research. This means that these themes are important and the main focus of the research. Example document titles: Role of NMDA receptors in brain function and cognition. Effects of novel cognitive enhancers on memory formation in rats. Effect of receptor modulators on cognitive enhancement in animal models.
Basic Themes (Lower-Right Quadrant):
Keywords: cognitive, enhancer, enhancer. Meaning: Basic themes are fundamental topics central to the field of research but are not yet well-developed. These are the foundations from which more specialized research can be developed. Example Document Titles: Overview of cognitive enhancers: mechanisms and applications. Cognitive enhancers: A review of their efficacy and safety. Evolution of cognitive enhancer research: From theory to practice.
Emerging or Declining Themes (Lower-Left Quadrant):
Keywords: study, patients, disorder, cognitive enhancers, enhancer. Meaning: Emerging and declining themes are topics that are either newly developing or losing relevance. This means that these are new areas being developed or possibly declining, if no significant new findings are made. Example Document Titles: Clinical studies of cognitive enhancers in patients with cognitive disorders. Role of cognitive enhancers in the management of cognitive disorders. Emerging trends in cognitive enhancer research: a clinical perspective.
Thematic Evolution
According to Figure 14, there was an evolution of changes in themes in research from 1988 to 2014 with the keywords cognitive, disease, receptor, effects, and memory. The theme then changed in 2015–2024 to effects, disease, study, cognition, and review.
Thematic Evolution.
Topic Dendogram
According to Figure 15. There are 2 large clusters According to keywords. There are 2 clusters of blue and red.
Dendogram.
Qualitative Analysis - refer to extended data for table 1 ^ 1420 ^)
Results and Discussion
Ginkgo biloba, also known as the maidenhair tree, is a living species of the order Ginkgoales, which first appeared over 290 million years ago. This plant has been known and developed by Chinese and Japanese cultures for thousands of years, and is often planted in temple gardens. ^ 1415 ^ This tree is valued not only for its resilience, but also for its therapeutic properties, which have been utilized in traditional medicine for centuries. In ancient China, Ginkgo biloba leaves have been used in medicinal practices to address respiratory disorders and improve blood circulation. ^ 1416 ^
The use of G. biloba as medicine has been documented in various ancient medical texts. In traditional Chinese medicine, ginkgo leaves are often made into tea or liquid extracts for use as a tonic to improve blood flow and address digestive and respiratory issues. Over time, the use of G. biloba has spread to various cultures worldwide, including Japan and Korea, where it continues to be valued for its health benefits. ^ 1417 ^
With advancements in pharmaceutical technology, G. biloba extracts have been formulated more efficiently to maximize their therapeutic benefits. The most commonly known standardized extract is EGb 761, which contains 24% flavonoid glycosides and 6% terpenoids. This formulation ensures consistency and product quality. The extract is used in various supplements including tablets, capsules, and liquids. ^ 1418 ^
The usual dosage for G. biloba supplements is 40 mg three times a day or 80 mg twice a day, with a maximum dose not exceeding 240 mg/day. This dosage is based on research showing the effectiveness and safety of these doses in improving cognitive function and reducing the symptoms associated with cognitive disorders. Studies have also indicated that proper dosing can have significant effects without causing harmful side effects. ^ 1419 ^
Ginkgo biloba has various complex mechanisms. One of the primary mechanisms is the enhancement of blood flow, especially to the brain, through its vasodilator effect. This helps improve oxygenation and nutrient delivery to brain cells, which in turn can enhance cognitive function. Additionally, G. biloba contains flavonoids and terpenoids with antioxidant properties, which help protect brain cells from oxidative damage caused by free radicals.
In addition to enhancing blood flow, flavonoids in G. biloba also have strong antioxidant effects. These antioxidants scavenge free radicals, which can damage cells and tissues in the body. On the other hand, terpenoids have anti-inflammatory properties that help reduce inflammation, which can cause tissue damage and cognitive disorders. The combination of antioxidant and anti-inflammatory effects makes G. biloba an effective therapeutic agent for protecting and improving brain function.
In the modern era, G. biloba has become the subject of various clinical studies investigating its effectiveness in various health conditions. One of the most prominent areas of research is its use in the treatment of dementia and mild cognitive impairment. Studies have shown that G. biloba extract can help improve memory, attention, and overall cognitive function in individuals with mild-to-moderate cognitive impairment.
Although G. biloba is generally considered safe, some side effects have been reported, including headache, dizziness, digestive issues, and allergic reactions. Therefore, it is important to follow the recommended dosage and consult with a healthcare professional before starting Ginkgo biloba supplements, especially for individuals who are taking other medications or have certain health conditions.
Some Ginkgo biloba products available on the market include Cereton, Cerviboost, Gingkan, Ginkgo Biloba Capsule, and GNC Ginkgo Biloba Plus. These products are available in various forms including tablets, capsules, and syrups. Each product typically lists the standardized content of G. biloba extract, making it easier for consumers to choose according to their needs. ^ 1419 ^
Many clinical trials have investigated the effectiveness of G. biloba in various health conditions. These studies included diverse populations, including healthy individuals, patients with dementia, and individuals with mild cognitive impairment. Clinical trials have shown that G. biloba can help improve cognitive function and memory, as well as reduce symptoms of dementia and other cognitive disorders. Dosage standardization of G. biloba has also been carried out to ensure consistency and safety during its use.
Further research has shown that G. biloba can affect neurotransmitters in the brain. For instance, G. biloba extract has been found to increase serotonin and dopamine levels, which play key roles in mood regulation and cognitive function. This indicates that in addition to its vasodilator and antioxidant effects, G. biloba can also influence biochemical pathways in the brain that contribute to improved cognitive function.
Research has shown that G. biloba can provide significant benefits in high-risk populations, such as the elderly and individuals with a genetic predisposition to cognitive disorders. In these populations, the use of G. biloba has been associated with a slower rate of cognitive decline and an overall improvement in quality of life. This underscores the potential of G. biloba as an effective preventive intervention. ^ 1415 ^
To ensure the quality and safety of G. biloba products, strict regulations have been established in many countries. Marketed products must meet specific standards regarding the content and purity of the G. biloba extract. This includes standards for the concentration of flavonoid glycosides and terpenoids as well as testing for contaminants that may be present in the final product. ^ 1417 ^
Additionally, comparative studies between G. biloba and other cognitive agents, such as donepezil and memantine, have been conducted. These studies aimed to determine the relative effectiveness of G. biloba compared with more commonly used medications in the treatment of dementia and cognitive disorders. The results of these studies indicated that G. biloba has a unique benefit and risk profile, making it an attractive option for use in combination with other therapies.
Although many studies have shown the benefits of G. biloba, there are still challenges in terms of the research methodology and variability of results. Further research is needed to understand the precise mechanisms of action and to determine the optimal dosage for various populations and health conditions. Further efforts are required to enhance the regulation and standardization of Ginkgo biloba products in the global market.
Conclusions
In conclusion, G. biloba has great potential as a cognitive enhancer that can be used in various health conditions. Through extensive clinical trials and research, we gained a better understanding of the mechanisms of action, safe dosages, and potential benefits. A more integrated approach and stricter regulations will ensure that G. biloba can be used effectively and safely in practice.
Future research should focus on larger-scale clinical trials with better-designed studies to reduce bias and to improve the validity of the results. Further studies are needed to explore the potential use of G. biloba in combination with other therapies and to understand the long-term effects of its use.
Ethics and consent
Ethical approval and consent were not required.
Reporting guidelines
Figshare: PRISMA-ScR checklist and flow chart: Gingko Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus data Base. A bibliometric studi from 1988 to 2024,
DOI: 10.6084/m9.figshare.28081724 ( https://doi.org/10.6084/m9.figshare.28081724.v1) ^ 1420 ^
The project contains the following reporting guidelines:
- • PRISMA_2020_checklist_AYS
- • PRISMA_2020_flow_diagram_new_AYS
The data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Software availability
VOSviewer software is an open-access tool that can be used as a cost-effective method for scientometric analysis Biblioshiny
Author Contribution
AYS conducted research, gathered data, performed statistical analysis, and produced discussions and conclusions, including TDS, RV, and DAYS editing.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Smith J : Ethical considerations in the use of cognitive enhancers. Neuroethics. 2020;13(1):45–58.
- 2Brown A Brown A Green B : J. Neurosci. 2019;2019(39):123–135.
- 3White R : Regulatory challenges in the development of cognitive enhancers. J. Law Med. 2018;35(3):201–210.
- 4Johnson C : The impact of cognitive enhancers on academic performance: A meta-analysis. J. Educ. Psychol. 2021;113(2):234–245.
- 5Porsolt RD Lenègre A Avril I : Antagonism by exifone, a new cognitive enhancing agent, of the amnesias induced by four benzodiazepines in mice. Psychopharmacology. 1988;95(3):291–297. 10.1007/BF 00181936 2901124 · doi ↗ · pubmed ↗
- 6GroóD PálosiÉ Szporny L : Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats. Drug Dev. Res. 1988;15(1):75–85. 10.1002/ddr.430150108 · doi ↗
- 7MorèL Privitera L Lopes M : MSK 1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF. Neuropharmacology. 2024;261:110110. 10.1016/j.neuropharm.2024.110110 39128584 · doi ↗ · pubmed ↗
- 8Dorer CL Manktelow AE Allanson J : Methylphenidate-mediated motor control network enhancement in patients with traumatic brain injury. Brain Inj. 2018;32(8):1040–1049. 10.1080/02699052.2018.1469166 29738277 · doi ↗ · pubmed ↗